Jennifer Jantz, MD
Cardiovascular Disease · New York, NYNPI 1184890006
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Abbott at 53.7% of the total. 2025 is the largest year on record at $5,852, more than ten times the $52 reported in 2019.
Across 81 payments — averaging $177.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Edwards Lifesciences$4K
- Ancora Heart, Inc.$1K
- Philips North America LLC$616
- Amgen$389
- Esperion Therapeutics, Inc.$253
- plus $435 from 5 others
What the payments were for
- Speaking & faculty fees$3,00021%
- Travel & lodging$8,30558%
- Food & beverage$2,99021%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 43 | $7,696 |
| Edwards Lifesciences | 22 | $3,670 |
| Ancora Heart, Inc. | 5 | $1,280 |
| Philips North America LLC | 2 | $616 |
| Amgen | 1 | $389 |
| Esperion Therapeutics, Inc. | 2 | $253 |
| Boston Scientific | 2 | $190 |
| Heartflow, Inc. | 1 | $150 |
| AstraZeneca | 1 | $43 |
| Braemar Manufacturing, LLC | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$4,027
- NAVITOR$1,293
- AccuCinch$1,280
- MitraClip$635
- (9525) Intracardiac Und$616
- NEXLETOL$253
- WATCHMAN FLX$166
- NEXLIZET$150
- FFRct$150
How this compares
$14,339 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.